Page 154 - CW E-Magazine (6-8-2024)

Pharmaceuticals

REGULATORY CLEARANCE
Cipla set to begin supplies to US from China plant

later this year

Mumbai-based drug fi rm, Cipla, supply to the US by the second half of Mr. Vohra informed shareholders that
expects to commence supplies to the FY 2024- 25,” Mr. Vohra said. the company is looking to target new
US market from its China facility in therapeutic areas like obesity-related
the second half of the current fi scal Sharing updates about other plants, diseases, and liver conditions while
after getting approval from the Ameri- he noted that the facilities of Patalganga investing heavily in tech-based solutions
can health regulator, according to and Kurkumbh in India were also for various ailments. The company is
its MD and global CEO, Mr. Umang cleared with a VAI (voluntary action also looking to build capabilities and
Vohra. indicated). “Our Goa site was issued continue to drive stewardship activi-
observations and our Indore plant is ties to counter the global threat of anti-
Addressing shareholders in the currently being remediated. Finding microbial resistance (AMR). Similar
company’s ‘Annual Report for 2023-24’, resolution for these regulatory issues efforts have also been planned in the
he noted that the company is working continues to be our top priority,” he areas of mental health and oncology,
with the USFDA to resolve issues with informed. he informed the company shareholders.
its various domestic plants. Moreover, the company is investing
The company has worked exten- heavily in new-age tech-based solu-
“Although we saw challenging sively to remediate its sites, creating a tions like CAR-T cell therapy, peptides,
phases with USFDA audits, I am glad blueprint for solid expansion in India oligonucleotides and biosimilars that
to report that our China facility cleared and is working closely with the USFDA will create a large-scale impact in the
the USFDA audit and is expected to to remediate these sites, he added. future, he added.
CONSOLIDATION
Mankind Pharma to acquire BSV from Advent

for over Rs. 13,600-cr

Mankind Pharma has agreed to care with established complex R&D BSV has developed recombinant
acquire biotech company BSV Group, tech platforms,” it said. and niche biologic products in-house,
(formerly Bharat Serum & Vaccines) demonstrating its strong R&D capa-
from private equity fi rm, Advent “BSV’s acquisition represents a bilities and boasts of a robust branded
International, the company said in a pivotal milestone in Mankind’s jour- product portfolio across women’s
release. ney, establishing us as market leader health, fertility and critical care. It
in Indian women’s health and fertility reported revenues of Rs. 1,723-crore in
The Delhi-based fi rm said it has segment. We believe women’s health FY24, delivering a 20% y-o-y growth.
entered into a defi nitive agreement to and fertility segment has massive The company has a niche portfolio
acquire a 100 percent stake in BSV opportunity along with strong growth offering in women’s health, encompass-
from Advent, for an enterprise value visibility globally, led by structural ing the entire lifecycle – from fertility
of around Rs. 13,630-crore, subject to tailwinds,” said Mr. Rajeev Juneja, to post-pregnancy. Advent International,
closing related adjustments. Vice-Chairman and MD, Mankind which had acquired BSV in 2019 in
Pharma. two transactions, had put the company
“This strategic move marks a signi- on the block late last year and the
fi cant leap for Mankind Pharma, positio- Mankind Pharma pipped the com- process has been going on for quite
ning it as a market leader in the bine of Baring Private Equity and a while with several PE fi rms as well
Indian women’s health and fertility Abu Dhabi Investment Authority that as pharmaceutical companies showing
drug market alongside access to other had bid a little over Rs 13,000-crore, interest and submitting non-binding
high entry barrier products in critical according to reports. bids.

154 Chemical Weekly August 6, 2024

Contents Index to Advertisers Index to Products Advertised